These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 25196370)

  • 21. A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design.
    D'Argenio DA; Wilson CB
    Immunity; 2010 Oct; 33(4):437-40. PubMed ID: 21029955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 2020 vision for vaccines against HIV, tuberculosis and malaria.
    Rappuoli R; Aderem A
    Nature; 2011 May; 473(7348):463-9. PubMed ID: 21614073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Malaria kills over 1 million people every year. Genomic mapping of malaria parasite and mosquito raise hope for a vaccine as well as more effective drugs].
    Kahl U
    Lakartidningen; 2003 Mar; 100(12):1042-7. PubMed ID: 12693137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Malaria Vaccine Epidemiology and Evaluation Project of Papua New Guinea: rationale and baseline studies.
    Alpers MP; al-Yaman F; Beck HP; Bhatia KK; Hii J; Lewis DJ; Paru R; Smith TA
    P N G Med J; 1992 Dec; 35(4):285-97. PubMed ID: 1341090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development.
    Inoue M; Tang J; Miyakoda M; Kaneko O; Yui K; Culleton R
    Int J Parasitol; 2012 Aug; 42(9):859-70. PubMed ID: 22846785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methods for determining vaccine efficacy and effectiveness and the main barriers to developing a fully deployable malaria vaccine.
    Guinovart C; Alonso PL
    Am J Trop Med Hyg; 2007 Dec; 77(6 Suppl):276-81. PubMed ID: 18165503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case for whole-parasite malaria vaccines.
    Wykes M; Good MF
    Int J Parasitol; 2007 Jun; 37(7):705-12. PubMed ID: 17408673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen--the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1.
    Ma C; Wang L; Webster DE; Campbell AE; Coppel RL
    Appl Microbiol Biotechnol; 2012 Apr; 94(1):151-61. PubMed ID: 22170105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The path of malaria vaccine development: challenges and perspectives.
    Arama C; Troye-Blomberg M
    J Intern Med; 2014 May; 275(5):456-66. PubMed ID: 24635625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
    Moore AC; Hill AV
    Immunol Rev; 2004 Jun; 199():126-43. PubMed ID: 15233731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NIAID meeting report: improving malaria vaccine strategies through the application of immunological principles.
    Mo AX; Augustine AD
    Vaccine; 2014 Feb; 32(10):1132-8. PubMed ID: 24060568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review.
    Epstein JE; Richie TL
    Curr Opin Infect Dis; 2013 Oct; 26(5):420-8. PubMed ID: 23982233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
    Breman JG; Alilio MS; Mills A
    Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric parasites as tools to study Plasmodium immunology and assess malaria vaccines.
    Cockburn I
    Methods Mol Biol; 2013; 923():465-79. PubMed ID: 22990798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malaria vaccine design: immunological considerations.
    Good MF; Doolan DL
    Immunity; 2010 Oct; 33(4):555-66. PubMed ID: 21029965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malaria--there could be a third way.
    Miles MA
    Nature; 2003 Jan; 421(6918):13. PubMed ID: 12511928
    [No Abstract]   [Full Text] [Related]  

  • 38. Malaria vaccine.
    Khurana SK; Talib VH
    Indian J Pathol Microbiol; 1996 Dec; 39(5):433-41. PubMed ID: 9002371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of malaria vaccines that block transmission of parasites by mosquito vectors.
    Hisaeda H; Yasutomo K
    J Med Invest; 2002 Aug; 49(3-4):118-23. PubMed ID: 12323000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in malaria control in sub-Saharan Africa: the vaccine perspective.
    Lusingu JP; Von Seidlein L
    Tanzan J Health Res; 2008 Oct; 10(4):253-66. PubMed ID: 19402588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.